Drug therapy for amyotrophic lateral sclerosis: Where are we now?

IDrugs. 2003 Feb;6(2):147-53.

Abstract

In the 60 years since Lou Gehrig died from amyotrophic lateral sclerosis (ALS) there have been numerous advances in our understanding of this disease. However, scant progress has been made regarding disease-altering treatments. Today most physicians still recommend vitamin E, which is the treatment Gehrig himself received. In this paper we will review what is currently known about the pathophysiology of ALS as well as the history of clinical trials in ALS. We indicate current and future directions in research and clinical trials, and also argue that a logical next step for clinical trials in ALS should be combination drug treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis / drug therapy*
  • Amyotrophic Lateral Sclerosis / enzymology
  • Amyotrophic Lateral Sclerosis / etiology
  • Animals
  • Antioxidants / therapeutic use
  • Clinical Trials as Topic
  • Creatine / therapeutic use
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Humans
  • Neuroprotective Agents / therapeutic use*
  • Riluzole / therapeutic use
  • Treatment Outcome

Substances

  • Antioxidants
  • Cyclooxygenase Inhibitors
  • Neuroprotective Agents
  • Riluzole
  • Creatine